Abstract

Barrett’s esophagus (BE) is the only known precursor of esophageal adenocarcinoma (EAC). This precancerous lesion can transform into low-grade and high-grade dysplasia, which may develop in the EAC. Therefore, the issues of dysplasia detection and monitoring and early diagnostics for the presence of EAC foci are extremely important factors in the surveillance of patients with BE progression. Histopathological examinations are regarded as the gold standard in the BE progression evaluation. They posses a large clinical utility in the identification of dysplasia and cancer risk stratification in patients with the BE. However, this method is a very subjective, and is heavily dependent on the knowledge and experience of the person conducting it. Therefore, it seems to be important to implement in the BE progression diagnostics sensitive and specific biomarkers that could be used as complementary tests. They could improve detection, stratification and monitoring of the progression of BE and the detection of the EAC early stages. Literature data concerning markers distinguishing between different stages of Barrett’s-related dysplasia and cancer is very scarce. In this article there we collected and characterized the most important data. Apart from this, there is a fairly large group of proteins and genes. Their expression levels allow for the detection of changes during the development of the BE progression. No studies have been carried out yet for their usefulness in differentiating between types of BE-related dysplasia and EAC, but we know that some of them could be useful as auxiliary markers differentiating between different stages of dysplasia and EAC. The article discusses those with the greatest potential.

References

• 1. Abdel-Latif M.M., Windle H., Terres A., Eidhin D.N., Kelleher D.,Reynolds J.V.: Helicobacter pylori extract induces nuclear factor-kappaB, activator protein-1, and cyclooxygenase-2 in esophageal epithelialcells. J. Gastrointest. Surg., 2006; 10: 551–562
  Google Scholar
• 2. Altaf K., Xiong J.J., la Iglesia D., Hickey L., Kaul A.: Meta-analysisof biomarkers predicting risk of malignant progression in Barrett’soesophagus. Br. J. Surg., 2017; 104: 493–502
  Google Scholar
• 3. Baghdadi J., Chaudhary N., Pei Z., Yang L.: Microbiome, innateimmunity, and esophageal adenocarcinoma. Clin. Lab. Med., 2014;34: 721–732
  Google Scholar
• 4. Bailey T., Biddlestone L., Shepherd N., Barr H., Warner P., JankowskiJ.: Altered cadherin and catenin complexes in the Barrett’s esophagus-dysplasia-adenocarcinoma sequence: correlation with diseaseprogression and dedifferentiation. Am. J. Pathol., 1998; 152: 135–144
  Google Scholar
• 5. Booth C.L., Thompson K.S.: Barrett’s esophagus: A review of diagnosticcriteria, clinical surveillance practices and new developments.J. Gastrointest. Oncol., 2012; 3: 232–242
  Google Scholar
• 6. Cardoso J., Mesquita M., Dias Pereira A., Bettencourt-Dias M., ChavesP., Pereira-Leal J.B.: CYR61 and TAZ upregulation and focal epithelialto mesenchymal transition may be early predictors of Barrett’sesophagus malignant progression. PLoS One, 2016; 11: e0161967
  Google Scholar
• 7. Cheong E., Igali L., Harvey I., Mole M., Lund E., Johnson I.T., RhodesM.: Cyclo-oxygenase-2 expression in Barrett’s oesophageal carcinogenesis:an immunohistochemical study. Aliment. Pharmacol.Ther., 2003; 17: 379–386
  Google Scholar
• 8. Chinyama C.N., Marshall R.E., Owen W.J., Mason R.C., KothariD., Wilkinson M.L., Sanderson J.D.: Expression of MUC1 and MUC2mucin gene products in Barrett’s metaplasia, dysplasia and adenocarcinoma:an immunopathological study with clinical correlation.Histopathology, 1999; 35: 517–524
  Google Scholar
• 9. Chu Y.X., Wang W.H., Dai Y., Teng G.G., Wang S.J.: Esophageal Helicobacterpylori colonization aggravates esophageal injury caused byreflux. World J. Gastroenterol., 2014; 20: 15715–15726
  Google Scholar
• 10. Ciriza-de-los-Ríos C.: Barrett’s esophagus – a review. Rev. Esp.Enferm. Dig., 2010; 102: 257–269
  Google Scholar
• 11. Critchley-Thorne R.J., Duits L.C., Prichard J.W., Davison J.M.,Jobe B.A., Campbell B.B., Zhang Y., Repa K.A., Reese L.M., Li J., DiehlD.L., Jhala N.C., Ginsberg G., DeMarshall M., Foxwell T. i wsp.: A tissuesystems pathology assay for high-risk Barrett’s esophagus. CancerEpidemiol. Biomarkers Prev., 2016; 25: 958–968
  Google Scholar
• 12. Cronin J., McAdam E., Danikas A., Tselepis C., Griffiths P., BaxterJ., Thomas L., Manson J., Jenkins G.: Epidermal growth factorreceptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinomaof the esophagus and may represent a biomarker ofhistological progression in Barrett’s esophagus (BE). Am. J. Gastroenterol.,2011; 106: 46–56
  Google Scholar
• 13. di Pietro M., Alzoubaidi D., Fitzgerald R.C.: Barrett’s esophagusand cancer risk: how research advances can impact clinical practice.Gut Liver, 2014; 8: 356–370
  Google Scholar
• 14. Dorer R., Odze R.D.: AMACR immunostaining is useful in detectingdysplastic epithelium in Barrett’s esophagus, ulcerative colitis,and Crohn’s disease. Am. J. Surg. Pathol., 2006; 30: 871–877
  Google Scholar
• 15. Duits L.C., Lao-Sirieix P., Wolf W.A., O’Donovan M., Galeano-DalmauN., Meijer S.L., Offerhaus G.J., Redman J., Crawte J., Zeki S., PouwR.E., Chak A., Shaheen N.J., Bergman J.J., Fitzgerald R.C.: A biomarkerpanel predicts progression of Barrett’s esophagus to esophagealadenocarcinoma. Dis. Esophagus, 2019; 32: 1–9
  Google Scholar
• 16. Dvorak K., Chavarria M., Payne C.M., Ramsey L., Crowley-WeberC., Dvorakova B., Dvorak B., Bernstein H., Holubec H., SamplinerR.E., Bernstein C., Prasad A., Green S.B., Garewal H.: Activation of theinterleukin-6/STAT3 antiapoptotic pathway in esophageal cells bybile acids and low pH: relevance to Barrett’s esophagus. Clin. CancerRes., 2007; 13: 5305–5313
  Google Scholar
• 17. Ecker B.L., Taylor L., Zhang P.J., Furth E.E., Ginsberg G.G., McMillanM.T., Datta J., Czerniecki B.J., Roses R.E.: HER3 expression isa marker of tumor progression in premalignant lesions of the gastroesophagealjunction. PLoS One, 2016; 11: e0161781
  Google Scholar
• 18. El-Serag H.B., Hollier J.M., Gravitt P., Alsarraj A., Younes M.:Human papillomavirus and the risk of Barrett’s esophagus. Dis. Esophagus,2013; 26: 517–521
  Google Scholar
• 19. Fouad Y.M., Mostafa I., Yehia R., El-Khayat H.: Biomarkers of Barrett’sesophagus. World J. Gastrointest. Pathophysiol., 2014; 5: 450–456
  Google Scholar
• 20. Gadara M.R., Gonzalez M., Cartun R.W., Ligato S.: IMP3 immunoreactivityis more sensitive than AMACR in detecting dysplasticepithelium and early adenocarcinoma in Barrett esophagus. Appl.Immunohistochem. Mol. Morphol., 2017; 25: 386–391
  Google Scholar
• 21. Gindea C., Birla R., Hoara P., Caragui A., Constantinoiu S.: Barrettesophagus: History, definition and etiopathogeny. J. Med. Life,2014; 7: 23–30
  Google Scholar
• 22. Goldblum J.R.: Barrett’s esophagus and Barrett’s-related dysplasia.Mod. Pathol., 2003; 16: 316–324
  Google Scholar
• 23. Goodarzi M., Correa A.M., Ajani J.A., Swisher S.G., HofstetterW.L., Guha S., Deavers M.T., Rashid A., Maru D.M.: Anti-phosphorylatedhistone H3 expression in Barrett’s esophagus, low-gradedysplasia, high-grade dysplasia, and adenocarcinoma. Mod. Pathol.,2009; 22: 1612–1621
  Google Scholar
• 24. Griffiths E.A., Pritchard S.A., McGrath S.M., Valentine H.R., PriceP.M., Welch I.M., West C.M.: Increasing expression of hypoxia-inducibleproteins in the Barrett’s metaplasia-dysplasia-adenocarcinomasequence. Br. J. Cancer, 2007; 96: 1377–1383
  Google Scholar
• 25. Grin A., Streutker C.J.: Histopathology in Barrett esophagus andBarrett esophagus-related dysplasia. Clin. Endosc., 2014; 47: 31–39
  Google Scholar
• 26. Herbella F.A., Patti M.G.: Gastroesophageal reflux disease:From pathophysiology to treatment. World J. Gastroenterol.,2010; 16: 3745–3749
  Google Scholar
• 27. Hong M.K., Laskin W.B., Herman B.E., Johnston M.H., Vargo J.J.,Steinberg S.M., Allegra C.J., Johnston P.G.: Expansion of the Ki-67proliferative compartment correlates with degree of dysplasia inBarrett’s esophagus. Cancer, 1995; 75: 423–429
  Google Scholar
• 28. Horvath B., Singh P., Xie H., Thota P.N., Sun X., Liu X.: Expressionof p53 predicts risk of prevalent and incident advanced neoplasia inpatients with Barrett’s esophagus and epithelial changes indefinitefor dysplasia. Gastroenterol. Rep., 2016; 4: 304–309
  Google Scholar
• 29. Jankowski J.A., Wright N.A., Meltzer S.J., Triadafilopoulos G., GeboesK., Casson A.G., Kerr D., Young L.S.: Molecular evolution of themetaplasia-dysplasia-adenocarcinoma sequence in the esophagus.Am. J. Pathol., 1999; 154: 965–973
  Google Scholar
• 30. Jiang K., Neill K., Cowden D., Klapman J., Eschrich S., Pimiento J.,Malafa M.P., Coppola D.: Expression of CAS/CSE1L, the cellular apoptosissusceptibility protein, correlates with neoplastic progressionin Barrett’s esophagus. Appl. Immunohistochem. Mol. Morphol.,2018; 26: 552–556
  Google Scholar
• 31. Jin Z., Cheng Y., Gu W., Zheng Y., Sato F., Mori Y., Olaru A.V., PaunB.C., Yang J., Kan T., Ito T., Hamilton J.P., Selaru F.M., Agarwal R., DavidS. i wsp.: A multicenter, double-blinded validation study of methylationbiomarkers for progression prediction in Barrett’s esophagus.Cancer Res., 2009; 69: 4112–4115
  Google Scholar
• 32. Karamchandani D.M., Lehman H.L., Ohanessian S.E., Massé J.,Welsh P.A., Odze R.D., Goldblum J.R., Berg A.S., Stairs D.B.: Increasingdiagnostic accuracy to grade dysplasia in Barrett’s esophagus usingan immunohistochemical panel for CDX2, p120ctn, c-Myc and Jagged1.Diagn. Pathol., 2016; 11: 23
  Google Scholar
• 33. Kastelein F., Biermann K., Steyerberg E.W., Verheij J., KalisvaartM., Looijenga L.H., Stoop H.A., Walter L., Kuipers E.J., SpaanderM.C., Bruno M.J., ProBar Study Group: Value of α-methylacyl-CoAracemase immunochemistry for predicting neoplastic progressionin Barrett’s oesophagus. Histopathology, 2013; 63: 630–639
  Google Scholar
• 34. Keswani R.N., Noffsinger A., Waxman I., Bissonnette M.: Clinicaluse of p53 in Barrett’s esophagus. Cancer Epidemiol. BiomarkersPrev., 2006; 15: 1243–1249
  Google Scholar
• 35. Kinra P., Gahlot G.P.S., Yadav R., Baloda V., Makharia G.K., GuptaS.D., Das P.: Histological assessment & use of immunohistochemicalmarkers for detection of dysplasia in Barrett’s esophageal mucosa.Pathol. Res. Pract., 2018; 214: 993–999
  Google Scholar
• 36. Kountourakis P., Ajani J.A., Davila M., Lee J.H., Bhutani M.S.,Izzo J.G.: Barrett’s esophagus: A review of biology and therapeuticapproaches. Gastrointest. Cancer Res., 2012; 5: 49–57
  Google Scholar
• 37. Krishnamoorthi R., Lewis J.T., Krishna M., Crews N.J., Johnson M.L.,Dierkhising R.A., Ginos B.F., Wang K.K., Wolfsen H.C., Fleischer D.E.,Ramirez F.C., Buttar N.S., Katzka D.A., Iyer P.G.: Predictors of progressionin Barrett’s esophagus with low-grade dysplasia: Results from a multicenterprospective BE registry. Am. J. Gastroenterol., 2017; 112: 867–873
  Google Scholar
• 38. Laerum O.D., Ovrebo K., Skarstein A., Christensen I.J., Alpízar-Alpízar W., Helgeland L., Danø K., Nielsen B.S., Illemann M.: Prognosisin adenocarcinomas of lower oesophagus, gastro-oesophagealjunction and cardia evaluated by uPAR-immunohistochemistry. Int.J. Cancer, 2012; 131: 558–569
  Google Scholar
• 39. Li Y., Wo J.M., Ray M.B., Jones W., Su R.R., Ellis S., Martin R.C.:Cyclooxygenase-2 and epithelial growth factor receptor up-regulationduring progression of Barrett’s esophagus to adenocarcinoma.World J. Gastroenterol., 2006; 12: 928–934
  Google Scholar
• 40. Lisovsky M., Falkowski O., Bhuiya T.: Expression of α-methylacylcoenzymeA racemase in dysplastic Barrett’s epithelium. Hum.Pathol., 2006; 37: 1601–1606
  Google Scholar
• 41. Ma C., Pai R.K.: Predictive value of immunohistochemistry inpre-malignant lesions of the gastrointestinal tract. Semin. Diagn.Pathol., 2015; 32: 334–343
  Google Scholar
• 42. Marketkar S., Li D., Yang D., Cao W.: TGR5 expression in benign,preneoplastic and neoplastic lesions of Barrett’s esophagus: Caseseries and findings. World. J. Gastroenterol., 2017; 23: 1338–1344
  Google Scholar
• 43. Maru D.M., Singh R.R., Hannah C., Albarracin C.T., Li Y.X., AbrahamR., Romans A.M., Yao H., Luthra M.G., Anandasabapathy S.,Swisher S.G., Hofstetter W.L., Rashid A., Luthra R.: MicroRNA-196ais a potential marker of progression during Barrett’s metaplasiadysplasia-invasive adenocarcinoma sequence in esophagus. Am. J.Pathol., 2009; 174: 1940–1948
  Google Scholar
• 44. Montgomery E.A., Hartmann D.P., Carr N.J., Holterman D.A., SobinL.H., Azumi N.: Barrett esophagus with dysplasia. Flow cytometricDNA analysis of routine, paraffin-embedded mucosal biopsies.Am. J. Clin. Pathol., 1996; 106: 298–304
  Google Scholar
• 45. Morrow D.J., Avissar N.E., Toia L., Redmond E.M., Watson T.J.,Jones C., Raymond D.P., Litle V., Peters J.H.: Pathogenesis of Barrett’sesophagus: bile acids inhibit the Notch signaling pathway with inductionof CDX2 gene expression in human esophageal cells. Surgery,2009; 146: 714–721
  Google Scholar
• 46. Naini B.V., Souza R.F., Odze R.D.: Barrett’s esophagus: A comprehensiveand contemporary review for pathologists. Am. J. Surg.Pathol., 2016; 40: e45–e66
  Google Scholar
• 47. Odze R.D.: Diagnosis and grading of dysplasia in Barrett’s oesophagus.J. Clin. Pathol., 2006; 59: 1029–1038
  Google Scholar
• 48. Oh D.S., Demeester S.R.: Pathophysiology and treatment of Barrett’sesophagus. World J. Gastroenterol., 2010; 16: 3762–3772
  Google Scholar
• 49. Onwuegbusi B.A., Aitchison A., Chin S.F., Kranjac T., Mills I.,Huang Y., Lao-Sirieix P., Caldas C., Fitzgerald R.C.: Impaired transforminggrowth factor β signalling in Barrett’s carcinogenesis dueto frequent SMAD4 inactivation. Gut, 2006; 55: 764–774
  Google Scholar
• 50. Ozcan H.E., Anuk T., Ozden O.: Expression profile and cellular localizationsof mucin proteins, CK7, and cytoplasmic p27 in Barrett’s esophagusand esophageal adenocarcinoma. Adv. Med. Sci., 2018; 63: 296–300
  Google Scholar
• 51. Pavlov K., Honing J., Meijer C., Boersma-van Ek W., Peters F.T.,van den Berg A., Karrenbeld A., Plukker J.T., Kruyt F.A., KleibeukerJ.H.: GATA6 expression in Barrett’s oesophagus and oesophagealadenocarcinoma. Dig. Liver. Dis., 2015; 47: 73–80
  Google Scholar
• 52. Quante M., Bhagat G., Abrams J.A., Marache F., Good P., LeeM.D., Lee Y., Friedman R., Asfaha S., Dubeykovskaya Z., MahmoodU., Figueiredo J.L., Kitajewski J., Shawber C., Lightdale C.J. i wsp.: Bileacid and inflammation activate gastric cardia stem cells in a mousemodel of Barrett-like metaplasia. Cancer Cell, 2012; 21: 36–51
  Google Scholar
• 53. Rajendra S., Wang B., Snow E.T., Sharma P., Pavey D., MerrettN., Ball M.J., Brain T., Fernando R., Robertson I.K.: Transcriptionallyactive human papillomavirus is strongly associated with Barrett’sdysplasia and esophageal adenocarcinoma. Am. J. Gastroenterol.,2013; 108: 1082–1093
  Google Scholar
• 54. Rajendra S., Yang T., Xuan W., Sharma P., Pavey D., Lee C.S., LeS., Collins J., Wang B.: Active human papillomavirus involvement inBarrett’s dysplasia and oesophageal adenocarcinoma is characterizedby wild-type p53 and aberrations of the retinoblastoma proteinpathway. Int. J. Cancer, 2017; 141: 2037–2049
  Google Scholar
• 55. Riegman P.H. Vissers K.J., Alers J.C., Geelen E., Hop W.C., TilanusH.W., van Dekken H.: Genomic alterations in malignant transformationof Barrett’s esophagus. Cancer Res., 2001; 61: 3164–3170
  Google Scholar
• 56. Scheil-Bertram S., Lorenz D., Ell C., Sheremet E., Fisseler-EckhoffA.: Expression of α-methylacyl coenzyme A racemase in the dysplasiacarcinoma sequence associated with Barrett’s esophagus. Mod.Pathol., 2008; 21: 961–967
  Google Scholar
• 57. Sharma N., Srivastava S., Kern F., Xian W., Yeoh K.G., Ming T.McKeon F., Ho K.Y.: CEACAM 6, a novel marker for the diagnosis ofBarrett’s esophagus. Dis. Esophagus, 2017; 30: 1–5
  Google Scholar
• 58. Soslow R.A., Ying L., Altorki N.K.: Expression of acidic fibroblastgrowth factor in Barrett’s esophagus and associated esophagealadenocarcinoma. J. Thorac. Cardiovasc. Surg., 1997; 114: 838–843
  Google Scholar
• 59. Souza R.F.: Biomarkers in Barrett’s esophagus. Tech. Gastrointest.Endosc., 2010; 12: 116–1212
  Google Scholar
• 60. Souza R.F, Krishnan K., Spechler S.J.: Acid, bile, and CDX: theABCs of making Barrett’s metaplasia. Am. J. Physiol. Gastrointest.Liver Physiol., 2008; 295: G211–G218
  Google Scholar
• 61. Stairs D.B., Nakagawa H., Klein-Szanto A., Mitchell S.D., SilbergD.G., Tobias J.W., Lynch J.P., Rustgi A.K.: Cdx1 and c-Myc foster theinitiation of transdifferentiation of the normal esophageal squamousepithelium toward Barrett’s esophagus. PLoS One, 2008; 3: e3534
  Google Scholar
• 62. Tamagawa Y., Ishimura N., Uno G., Yuki T., Kazumori H., IshiharaS., Amano Y., Kinoshita Y.: Notch signaling pathway and Cdx2expression in the development of Barrett’s esophagus. Lab. Invest.,2012; 92: 896–909
  Google Scholar
• 63. Thota P.N., Kistangari G., Esnakula A.K., Gonzalo D.H., Liu X.L.:Clinical significance and management of Barrett’s esophagus withepithelial changes indefinite for dysplasia. World J. Gastrointest.Pharmacol. Ther., 2016; 7: 406–411
  Google Scholar
• 64. Tselepis C., Perry I., Jankowski J.: Barrett’s esophagus: disregulationof cell cycling and intercellular adhesion in the metaplasiadysplasia-carcinoma sequence. Digestion, 2000; 61: 1–5
  Google Scholar
• 65. van Dekken H., Hop W.C., Tilanus H.W., Haringsma J., van derValk H., Wink J.C., Vissers K.J.: Immunohistochemical evaluation ofa panel of tumor cell markers during malignant progression in Barrettesophagus. Am. J. Clin. Pathol., 2008; 130: 745–753
  Google Scholar
• 66. van Olphen S.H., Ten Kate F.J., Doukas M., Kastelein F., SteyerbergE.W., Stoop H.A., Spaander M.C., Looijenga L.H., Bruno M.J., BiermannK., ProBar Study Group: Value of cyclin A immunohistochemistry forcancer risk stratification in Barrett esophagus surveillance: A multicentercase-control study. Medicine, 2016; 95: e5402
  Google Scholar
• 67. Volkweis B.S., Gurski R.R., Meurer L., Pretto G.G., Mazzini GdaS., Edelweiss M.I.: Ki-67 antigen overexpression is associated withthe metaplasia-adenocarcinoma sequence in Barrett’s esophagus.Gastroenterol. Res. Pract., 2012; 2012: 639748
  Google Scholar
• 68. Weimann A., Zimmermann M., Gross M., Slevogt H., Rieger A.,Morawietz L.: CDX2 and LI-cadherin expression in esophageal mucosa:use of both markers can facilitate the histologic diagnosis of Barrett’sesophagus and carcinoma. Int. J. Surg. Pathol., 2010; 18: 330–337
  Google Scholar
• 69. Williams L.J., Guernsey D.L., Casson A.G.: Biomarkers in the molecularpathogenesis of esophageal (Barrett) adenocarcinoma. Curr.Oncol., 2006; 13: 33–43
  Google Scholar
• 70. Wiseman E.F., Ang Y.S.: Risk factors for neoplastic progressionin Barrett’s esophagus. World J. Gastroenterol., 2011; 17: 3672–3683
  Google Scholar
• 71. Wong N.A., Wilding J., Bartlett S., Liu Y., Warren B.F., Piris J.,Maynard N., Marshall R., Bodmer W.F.: CDX1 is an important molecularmediator of Barrett’s metaplasia. Proc. Natl. Acad. Sci. USA,2005; 102: 7565–7570
  Google Scholar
• 72. Younes M., Brown K., Lauwers G.Y., Ergun G., Meriano F., SchmulenA.C., Barroso A., Ertan A.: p53 protein accumulation predictsmalignant progression in Barrett’s metaplasia: a prospective studyof 275 patients. Histopathology, 2017; 71: 27–33
  Google Scholar
• 73. Younes M., Ertan A., Lechago L.V., Somoano J., Lechago J.: Humanerythrocyte glucose transporter (Glut1) is immunohistochemicallydetected as a late event during malignant progression in Barrett’smetaplasia. Cancer Epidemiol. Biomarkers Prev., 1997; 6: 303–305
  Google Scholar
• 74. Zagorowicz E., Jankowski J.: Molecular changes in the progressionof Barrett’s oesophagus. Postgrad. Med. J., 2007; 83: 529–535
  Google Scholar

Full text